Late aortoenteric fistulae may occur in less than 1% of patients undergoing endovascular aneurysm repair (EVAR), with an increased risk in cases of emergency EVAR or those performed for pseudoaneurysm following previous aortic surgery. The data came from a study presented at the annual meeting of the European Society for Vascular Surgery (ESVS; 23–25 September, Porto, Portugal).
TVA Medical has announced clinical trial results from a prospective, multicentre clinical study evaluating the everlinQ endovascular arteriovenous fistula system. This medical technology creates haemodialysis access using vascular sites not traditionally used by surgeons for people with end-stage kidney disease.
AV Medical Technologies has received US Food and Drug Administration (FDA) for its Chameleon angioplasty balloon catheter.
A comprehensive study published in Anaesthesia has found that the only factor influencing ‘never events’ at individual hospitals is their size.
The 24-month results from the DEBAS clinical trial have been presented at the VEITHsymposium (17–21 November, New York, USA). Biotronik says that DEBAS is the first investigator-initiated trial to demonstrate the efficacy and safety of a novel combination therapy for peripheral artery disease using Passeo-18 Lux drug-coated balloon and Pulsar-18 self-expanding stent to treat peripheral artery disease in a complex patient population.
Endologix has announced the presentation of updated clinical data from the company’s EVAS FORWARD Global Registry, a post-market study that prospectively enrolled patients with abdominal aortic aneurysms who were treated with the Nellix endovascular aneurysm sealing system.
Gore has announced the nominees and opening of voting for the 2016 Pioneers in Performance Awards for North America. The announcement was made at the 2015 VEITHsymposium (17–21 November, New York, USA).
Endologix has announced the start of a physician-initiated registry of the Nellix endovascular aneurysm sealing (EVAS) system used with aortic branch stent grafts for the treatment of patients with complex abdominal aortic aneurysms.
The Excluder iliac branch endoprosthesis has exceeded 1,000 implants worldwide; a milestone that comes two years after the device received the CE mark in Europe. The device is currently commercially available in Europe and Australia, available through special access in Canada and is involved in a clinical trial in the USA.
JM Verhagen, professor and chief of Vascular Surgery, Erasmus University Medical Center in Rotterdam, the Netherlands, presented new data on the Endurant abdominal aortic aneurysm stent graft on the opening day of the VEITHsymposium (17–21 November, New York, USA).
According to new a study published in PLOS Medicine, a new clinical model can help predict the risk of venous thromboembolism (VTE) among patients with a leg case, enabling doctors to identify high risk cases.
Spectranetics has reported that its peripheral atherectomy device—the Turbo-Power laser atherectomy catheter—has received US Food and Drug Administration (FDA) 510(k) clearance for the treatment of in-stent restenosis (ISR).
Twelve-month results from the MAJESTIC trial evaluating the performance of the Eluvia drug-eluting stent demonstrated a primary patency rate of 100% amongst diabetic patients and no target lesion revascularisations in this subgroup. The data were presented at a Late-Breaking Trials session at the Vascular Interventional Advances annual conference (VIVA; 1–5 November, Las Vegas, USA).
Renal Dynamics’ (ReDy) third-generation Renal Denervation System has been granted CE mark approval for the treatment of resistant hypertension and is now commercially available on the European market.
Bristol-Myers Squibb and Pfizer have announced results from a post-hoc early time course subanalysis of the phase 3 AMPLIFY (Apixaban for the initial management of pulmonary embolism and deep vein thrombosis as first-line therapy) trial.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos